Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
HIV Med ; 17(10): 728-739, 2016 11.
Article in English | MEDLINE | ID: mdl-27186715

ABSTRACT

OBJECTIVES: Certain prescribed opioids have immunosuppressive properties, yet their impact on clinically relevant outcomes, including antiretroviral therapy (ART) response among HIV-infected patients, remains understudied. METHODS: Using the Veterans Aging Cohort Study data, we conducted a longitudinal analysis of 4358 HIV-infected patients initiating ART between 2002 and 2010 and then followed them for 24 months. The primary independent variable was prescribed opioid duration, categorized using pharmacy data as none prescribed, short-term (< 90 days) and long-term (≥ 90 days). Outcomes included CD4 cell count over time. Analyses adjusted for demographics, comorbid conditions, ART type and year of initiation, and overall disease severity [ascertained with the Veterans Aging Cohort Study (VACS) Index]. Sensitivity analyses examined whether effects varied according to baseline CD4 cell count, achievement of viral load suppression, and opioid properties (i.e. dose and known immunosuppressive properties). RESULTS: Compared to those with none, patients with short-term opioids had a similar increase in CD4 cell count (mean rise per year: 74 vs. 68 cells/µL; P = 0.11), as did those with long-term prescribed opioids (mean rise per year: 74 vs. 75 cells/µL; P = 0.98). In sensitivity analysis, compared with no opioids, the effects of short-term prescribed opioids were statistically significant among those with a baseline CD4 cell count ≥ 500 cells/µL (mean rise per year: 52 cells/µL for no opioids vs. 20 cells/µL for short-term opioids; P = 0.04); findings were otherwise unchanged. CONCLUSIONS: Despite immunosuppressive properties intrinsic to opioids, prescribed opioids appeared to have no effect on CD4 cell counts over 24 months among HIV-infected patients initiating ART.


Subject(s)
Analgesics, Opioid/adverse effects , Analgesics, Opioid/therapeutic use , Anti-Retroviral Agents/therapeutic use , HIV Infections/drug therapy , HIV Infections/pathology , Immunosuppressive Agents/adverse effects , Immunosuppressive Agents/therapeutic use , Adult , CD4 Lymphocyte Count , Female , Humans , Longitudinal Studies , Male , Middle Aged
2.
HIV Med ; 16(6): 346-54, 2015 Jul.
Article in English | MEDLINE | ID: mdl-25688937

ABSTRACT

OBJECTIVES: Community viral load (CVL) estimates vary based on analytic methods. We extended the CVL concept and used data from the Veterans Health Administration (VA) to determine trends in the health care system viral load (HSVL) and its sensitivity to varying definitions of the clinical population and assumptions regarding missing data. METHODS: We included HIV-infected patients in the Veterans Aging Cohort Study, 2000-2010, with at least one documented CD4 count, HIV-1 RNA or antiretroviral prescription (n = 37 318). We created 6-month intervals including patients with at least one visit in the past 2 years. We assessed temporal trends in clinical population size, patient clinical status and mean HSVL and explored the impact of varying definitions of the clinical population and assumptions about missing viral load. RESULTS: The clinical population size varied by definition, increasing from 16 000-19 000 patients in 2000 to 23 000-26 000 in 2010. The proportion of patients with suppressed HIV-1 RNA increased over time. Over 20% of patients had no viral load measured in a given interval or the past 2 years. Among patients with a current HIV-1 RNA, mean HSVL decreased from 97 800 HIV-1 RNA copies/mL in 2000 to 2000 copies/mL in 2010. When current HIV-1 RNA data were unavailable and the HSVL was recalculated using the last available HIV-1 RNA, HSVL decreased from 322 300 to 9900 copies/mL. HSVL was underestimated when using only current data in each interval. CONCLUSIONS: The CVL concept can be applied to a health care system, providing a measure of health care quality. Like CVL, HSVL estimates depend on definitions of the clinical population and assumptions about missing data.


Subject(s)
HIV Infections/diagnosis , Population Surveillance/methods , Viral Load , Adult , CD4 Lymphocyte Count , Cohort Studies , Female , HIV Infections/virology , HIV-1 , Humans , Male , Middle Aged , RNA, Viral/analysis , Veterans
3.
Arch Intern Med ; 161(20): 2458-63, 2001 Nov 12.
Article in English | MEDLINE | ID: mdl-11700158

ABSTRACT

BACKGROUND: Evidence-based clinical practice guidelines recommend the use of warfarin sodium for stroke prevention in most patients with atrial fibrillation (AF) who do not have risk factors for hemorrhagic complications, irrespective of age. METHODS: The medical records of all residents of a convenience sample of long-term care facilities in Connecticut (n = 21) were reviewed. The percentages of all patients with AF (AF patients) and ideal candidates for warfarin therapy (ie, AF patients with no risk factors for hemorrhage) who received warfarin were determined; for patients receiving warfarin, the percentage of days spent in the therapeutic range of international normalized ratio (INR) values (2.0-3.0) was also assessed. The relationship between receipt of warfarin and the presence of stroke and bleeding risk factors was assessed in multivariate models. RESULTS: Atrial fibrillation was present in 429 (17%) of the 2587 long-term care residents. Overall, 42% of AF patients were receiving warfarin. However, only 44 (53%) of 83 ideal candidates were receiving this therapy. In residents who received warfarin therapy, the therapeutic range of INR values was maintained only 51% of the time. The odds of receiving warfarin in the study sample decreased with increasing number of risk factors for bleeding and increased (nonsignificant trend) with increasing number of stroke risk factors present. CONCLUSIONS: Atrial fibrillation is very common among residents of long-term care facilities. Even among apparently ideal candidates, warfarin therapy is underused for stroke prevention in patients with AF. Prescribing decisions and monitoring related to warfarin therapy in the long-term care setting warrant improvement.


Subject(s)
Anticoagulants/therapeutic use , Atrial Fibrillation/complications , Atrial Fibrillation/drug therapy , Drug Utilization/standards , Guideline Adherence/standards , Nursing Homes/standards , Quality of Health Care , Stroke/etiology , Stroke/prevention & control , Warfarin/therapeutic use , Aged , Aged, 80 and over , Anticoagulants/adverse effects , Atrial Fibrillation/epidemiology , Connecticut/epidemiology , Contraindications , Drug Monitoring/standards , Female , Guideline Adherence/statistics & numerical data , Health Services Research , Hemorrhage/chemically induced , Hemorrhage/epidemiology , Humans , Logistic Models , Male , Multivariate Analysis , Patient Selection , Practice Guidelines as Topic , Prevalence , Retrospective Studies , Risk Factors , Stroke/epidemiology , Total Quality Management , Warfarin/adverse effects
4.
Arch Intern Med ; 160(22): 3385-91, 2000.
Article in English | MEDLINE | ID: mdl-11112230

ABSTRACT

BACKGROUND: It is unclear how outcomes of care for patients hospitalized for pneumonia have changed as patterns of health care delivery have changed during the 1990s. This study was performed to determine trends in outcomes of care for older patients hospitalized for pneumonia. METHODS: This retrospective analysis was based on Medicare claims and included most patients with pneumonia who were older than 65 years and admitted to acute care hospitals in Connecticut between October 1, 1991, and September 30, 1997 (fiscal years 1992-1997). We assessed the trends in hospital costs, discharge destination, hospital mortality rates, mortality rates within 30 days of discharge, and 30-day readmission rates for pneumonia. Multivariate logistic regression analyses were used to adjust for differences in patient characteristics. RESULTS: The mean (+/- SD) length of stay declined from 11.9 + 11.4 days to 7.7 + 7.2 days between 1992 and 1997. During this period, adjusted in-hospital mortality rates declined (P =.02), while the adjusted risk of discharge to a nursing facility increased (P<.001) and the adjusted risk of hospital readmission for pneumonia within 30 days of discharge increased (P =.05). The adjusted risk of death 30 days after discharge increased, although the difference was not statistically significant (P =.09). CONCLUSIONS: Between 1992 and 1997, the adjusted risks of mortality after discharge, placement in a nursing facility, and hospital readmission for pneumonia increased among older patients hospitalized for pneumonia, in association with a decline in mean hospital length of stay. These findings raise the question of whether the declining hospital length of stay has negatively affected patient outcomes. Arch Intern Med. 2000;160:3385-3391.


Subject(s)
Outcome Assessment, Health Care , Pneumonia/mortality , Aged , Aged, 80 and over , Connecticut/epidemiology , Female , Hospital Mortality , Humans , Length of Stay , Logistic Models , Male , Medicare , Middle Aged , Retrospective Studies
5.
Eval Health Prof ; 23(4): 409-21, 2000 Dec.
Article in English | MEDLINE | ID: mdl-11139868

ABSTRACT

Providing quality prenatal care to high-risk, pregnant adolescents represents an important challenge to health care providers and health plans. Using national prenatal care guidelines, this study sought to evaluate the quality of important processes and outcomes of prenatal care delivered to women age 21 years and younger enrolled in three health plans serving the Connecticut Medicaid population. Some important findings include 93% compliance with recommended processes of prenatal care, an 11% C-section rate, an average length of hospital stay of 4.0 days for women having a C-section, and a 10% premature delivery rate. Opportunities for improvement include 40% failing to begin prenatal care in the first trimester, 31% not receiving the recommended number of prenatal care visits, and 8% delivering a low-birth-weight infant. This study provides important descriptive information on processes and outcomes of care for pregnant adolescents within Medicaid Managed Care and also identifies opportunities for improvement.


Subject(s)
Managed Care Programs/standards , Medicaid/standards , Outcome and Process Assessment, Health Care , Prenatal Care/standards , Adolescent , Adult , Cesarean Section/statistics & numerical data , Connecticut , Female , Humans , Length of Stay/statistics & numerical data , Pregnancy , Pregnancy in Adolescence , Prenatal Care/statistics & numerical data , Program Evaluation , Quality Indicators, Health Care , United States
6.
Ethn Dis ; 9(3): 396-402, 1999.
Article in English | MEDLINE | ID: mdl-10600062

ABSTRACT

Annual counts, proportional distributions, and age-adjusted incidence rates of disease by stage at diagnosis are reported for 27,970 in situ and invasive breast cancers from the Connecticut Tumor Registry, 1986-1995. Odds ratios for the likelihood of late-stage disease by year of diagnosis, age category, race/ethnicity, and the socioeconomic level of community of residence are presented. More breast cancer is diagnosed today at earlier, treatable stages than was previously the case. Nonetheless, young women, non-whites, and residents of low-to-moderate income census tracts were all at increased risk of being diagnosed with late-stage disease than were their respective reference groups. From 1986 through 1990, there was little change in the greater likelihood that non-whites and disadvantaged women would be diagnosed with late-stage disease. For 1990-95, however, the disparity in late-stage diagnosis by race/ethnicity and socioeconomic standing was greatly decreased.


Subject(s)
Breast Neoplasms/diagnosis , Breast Neoplasms/ethnology , Adult , Aged , Connecticut/epidemiology , Female , Humans , Incidence , Middle Aged , Odds Ratio , Socioeconomic Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...